{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:54:15Z","timestamp":1790351655121,"version":"4.1.0"},"reference-count":132,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100023673","name":"Deanship of Scientific Research, Imam Mohammed Ibn Saud Islamic University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023673","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002713","name":"Imam Mohammed Ibn Saud Islamic University","doi-asserted-by":"publisher","award":["IMSIU-DDRSP-RP25"],"award-info":[{"award-number":["IMSIU-DDRSP-RP25"]}],"id":[{"id":"10.13039\/501100002713","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.bcp.2025.117619","type":"journal-article","created":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T16:01:00Z","timestamp":1765036860000},"page":"117619","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Interplay between hypoxia-inducible factors and apoptosis in glioblastoma"],"prefix":"10.1016","volume":"244","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6649-3694","authenticated-orcid":false,"given":"Md Ataur","family":"Rahman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maroua","family":"Jalouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Al-Zharani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khandoker Asiqur","family":"Rahaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdel Halim","family":"Harrath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.bcp.2025.117619_b0005","doi-asserted-by":"crossref","DOI":"10.1111\/bpa.13062","article-title":"Classification of adult\u2010type diffuse gliomas: Impact of the World Health Organization 2021 update","volume":"32","author":"Whitfield","year":"2022","journal-title":"Brain Pathol."},{"issue":"7","key":"10.1016\/j.bcp.2025.117619_b0010","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.3390\/curroncol31070296","article-title":"Temozolomide (TMZ) in the treatment of glioblastoma multiforme\u2014a literature review and clinical outcomes","volume":"31","author":"Jezierza\u0144ski","year":"2024","journal-title":"Curr. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2025.117619_b0015","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.trecan.2022.09.005","article-title":"Challenges in glioblastoma research: focus on the tumor microenvironment","volume":"9","author":"Bikfalvi","year":"2023","journal-title":"Trends Cancer"},{"issue":"22","key":"10.1016\/j.bcp.2025.117619_b0020","doi-asserted-by":"crossref","first-page":"12608","DOI":"10.3390\/ijms222212608","article-title":"Hypoxia: the cornerstone of glioblastoma","volume":"22","author":"Dom\u00e8nech","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2025.117619_b0025","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/s41598-024-83730-8","article-title":"Mechanistic insights into gut microbe derived siderophores and PHD2 interactions with implications for HIF-1\u03b1 stabilization","volume":"15","author":"Patel","year":"2025","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.bcp.2025.117619_b0030","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.3390\/ijms25042060","article-title":"Therapeutic targeting of hypoxia-inducible factors in cancer","volume":"25","author":"Musleh Ud Din","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.bcp.2025.117619_b0035","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.3390\/cancers16112089","article-title":"Understanding the significance of hypoxia-inducible factors (HIFs) in glioblastoma: a systematic review","volume":"16","author":"Begagi\u0107","year":"2024","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.bcp.2025.117619_b0040","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41419-021-03505-1","article-title":"The crosstalk between HIFs and mitochondrial dysfunctions in cancer development","volume":"12","author":"Bao","year":"2021","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.bcp.2025.117619_b0045","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1146\/annurev-immunol-042617-053010","article-title":"Apoptosis and clearance of apoptotic cells","volume":"36","author":"Nagata","year":"2018","journal-title":"Annu. Rev. Immunol."},{"issue":"7","key":"10.1016\/j.bcp.2025.117619_b0050","doi-asserted-by":"crossref","first-page":"796","DOI":"10.3390\/metabo13070796","article-title":"Cancer metabolism: the role of ROS in DNA damage and induction of apoptosis in cancer cells","volume":"13","author":"Zhao","year":"2023","journal-title":"Metabolites"},{"key":"10.1016\/j.bcp.2025.117619_b0055","series-title":"Modulating the Hippo Pathway as Novel Strategy for Beta-cell-Directed Therapy in Diabetes","author":"Lup\u0161e","year":"2022"},{"issue":"4","key":"10.1016\/j.bcp.2025.117619_b0060","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.5530\/ctbp.2024.4.52","article-title":"BCL protein and it\u2019s intrinsic apoptotic pathway: a literature review","volume":"18","author":"Mohan","year":"2024","journal-title":"Current Trends Biotechnol. Pharmacy"},{"key":"10.1016\/j.bcp.2025.117619_b0065","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.biopha.2018.11.005","article-title":"Curcumin pretreatment protects against hypoxia\/reoxgenation injury via improvement of mitochondrial function, destabilization of HIF-1\u03b1 and activation of Epac1-Akt pathway in rat bone marrow mesenchymal stem cells","volume":"109","author":"Wang","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bcp.2025.117619_b0070","article-title":"The interplay between tumor suppressor p53 and hypoxia signaling pathways in cancer","volume":"9","author":"Zhang","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.bcp.2025.117619_b0075","doi-asserted-by":"crossref","unstructured":"M.S. Asl, A. Iranmehr, S. Hanaei, Mechanisms of chemoresistance in high-grade gliomas. Brain Tumors: An Interdisciplinary Approach, 2023, pp. 595\u2013619.","DOI":"10.1007\/16833_2023_185"},{"issue":"4","key":"10.1016\/j.bcp.2025.117619_b0080","doi-asserted-by":"crossref","first-page":"572","DOI":"10.3390\/biom11040572","article-title":"Overcoming TRAIL resistance for glioblastoma treatment","volume":"11","author":"Deng","year":"2021","journal-title":"Biomolecules"},{"issue":"9","key":"10.1016\/j.bcp.2025.117619_b0085","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.3390\/cancers14092291","article-title":"Hypoxia as a modulator of inflammation and immune response in cancer","volume":"14","author":"Castillo-Rodr\u00edguez","year":"2022","journal-title":"Cancers"},{"issue":"9","key":"10.1016\/j.bcp.2025.117619_b0090","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.3390\/cancers15092613","article-title":"The role of hypoxia and cancer stem cells in development of glioblastoma","volume":"15","author":"Shi","year":"2023","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.bcp.2025.117619_b0095","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.3390\/ijms26041752","article-title":"Emerging role of hypoxia-inducible factors (HIFs) in modulating autophagy: perspectives on cancer therapy","volume":"26","author":"Jalouli","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.bcp.2025.117619_b0100","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.3390\/cancers13112813","article-title":"An overview of the recent development of anticancer agents targeting the HIF-1 transcription factor","volume":"13","author":"Shirai","year":"2021","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.bcp.2025.117619_b0105","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.3390\/cancers12113353","article-title":"Bh3 mimetics for the treatment of b-cell malignancies\u2014insights and lessons from the clinic","volume":"12","author":"Lin","year":"2020","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.bcp.2025.117619_b0110","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.3390\/ph17101389","article-title":"Targeting tumor hypoxia with nanoparticle-based therapies: challenges, opportunities, and clinical implications","volume":"17","author":"Debnath","year":"2024","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bcp.2025.117619_b0115","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1384249","article-title":"Hypoxia within the glioblastoma tumor microenvironment: a master saboteur of novel treatments","volume":"15","author":"Feldman","year":"2024","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.bcp.2025.117619_b0120","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2174\/1874467214666210120154929","article-title":"Hypoxia-inducible factor (HIF): fuel for cancer progression","volume":"14","author":"Satija","year":"2021","journal-title":"Curr. Mol. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117619_b0125","series-title":"Biophysical Characterization of Prolyl Hydroxylation-Dependent HIF-1\u03b1 Degradation","author":"He","year":"2024"},{"issue":"5","key":"10.1016\/j.bcp.2025.117619_b0130","doi-asserted-by":"crossref","first-page":"950","DOI":"10.3390\/ijms18050950","article-title":"Hypoxia, HIF, and associated signaling networks in chronic kidney disease","volume":"18","author":"Liu","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.bcp.2025.117619_b0135","doi-asserted-by":"crossref","first-page":"693","DOI":"10.3390\/cells14100693","article-title":"Cooperative role of carbonic anhydrase IX\/XII in driving tumor invasion and metastasis: a novel targeted therapeutic strategy","volume":"14","author":"Yang","year":"2025","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.bcp.2025.117619_b0140","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1113\/JP280572","article-title":"Regulation of glycolysis by the hypoxia\u2010inducible factor (HIF): implications for cellular physiology","volume":"599","author":"Kierans","year":"2021","journal-title":"J. Physiol."},{"key":"10.1016\/j.bcp.2025.117619_b0145","series-title":"Cancer Stem Cells and Cancer Therapy","first-page":"29","article-title":"Hypoxia, stem cells and cancer stem cells","author":"Manian","year":"2025"},{"issue":"3","key":"10.1016\/j.bcp.2025.117619_b0150","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1002\/med.21771","article-title":"The role of hypoxia\u2010inducible factor 1 in tumor immune evasion","volume":"41","author":"You","year":"2021","journal-title":"Med. Res. Rev."},{"issue":"5","key":"10.1016\/j.bcp.2025.117619_b0155","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.3390\/cells10051006","article-title":"Tumour hypoxia-mediated immunosuppression: mechanisms and therapeutic approaches to improve cancer immunotherapy","volume":"10","author":"Fu","year":"2021","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.bcp.2025.117619_b0160","doi-asserted-by":"crossref","first-page":"657","DOI":"10.3892\/or.2016.5309","article-title":"Advances in the targeting of HIF-1\u03b1 and future therapeutic strategies for glioblastoma multiforme","volume":"37","author":"Wang","year":"2017","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bcp.2025.117619_b0165","doi-asserted-by":"crossref","DOI":"10.1146\/annurev-genet-012125-083359","article-title":"Cell death, compensatory proliferation, and cell competition","volume":"59","author":"Bergmann","year":"2025","journal-title":"Annu. Rev. Genet."},{"issue":"1","key":"10.1016\/j.bcp.2025.117619_b0170","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12935-025-03721-1","article-title":"Amino acid metabolism in glioblastoma pathogenesis, immune evasion, and treatment resistance","volume":"25","author":"Srivastava","year":"2025","journal-title":"Cancer Cell Int."},{"issue":"4","key":"10.1016\/j.bcp.2025.117619_b0175","article-title":"Oxidative stress and chronic myeloid Leukemia: A balance between ROS-mediated Pro- and Anti-apoptotic effects of tyrosine kinase inhibitors","volume":"13","author":"Allegra","year":"2024","journal-title":"Antioxidants (Basel)"},{"issue":"8","key":"10.1016\/j.bcp.2025.117619_b0180","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1038\/s41418-025-01481-z","article-title":"The BCL-2 protein family: from discovery to drug development","volume":"32","author":"Croce","year":"2025","journal-title":"Cell Death Differ."},{"issue":"1","key":"10.1016\/j.bcp.2025.117619_b0185","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/07357907.2024.2445528","article-title":"A Comprehensive Insight into apoptosis: molecular mechanisms, signaling pathways, and modulating therapeutics","volume":"43","author":"Mosadegh","year":"2025","journal-title":"Cancer Invest."},{"issue":"1","key":"10.1016\/j.bcp.2025.117619_b0190","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41392-023-01347-1","article-title":"Targeting p53 pathways: mechanisms, structures, and advances in therapy","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"6","key":"10.1016\/j.bcp.2025.117619_b0195","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.tig.2022.02.010","article-title":"The p53 network: cellular and systemic DNA damage responses in cancer and aging","volume":"38","author":"Vaddavalli","year":"2022","journal-title":"Trends Genet."},{"issue":"2","key":"10.1016\/j.bcp.2025.117619_b0200","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a041053","article-title":"The death receptor pathway of apoptosis","volume":"14","author":"Green","year":"2022","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"4","key":"10.1016\/j.bcp.2025.117619_b0205","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1023\/A:1016167228059","article-title":"Initiator caspases in apoptosis signaling pathways","volume":"7","author":"Chen","year":"2002","journal-title":"Apoptosis"},{"issue":"11","key":"10.1016\/j.bcp.2025.117619_b0210","article-title":"Types of cell death from a molecular perspective","volume":"12","author":"Hajibabaie","year":"2023","journal-title":"Biology (Basel)"},{"issue":"7","key":"10.1016\/j.bcp.2025.117619_b0215","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1007\/s10495-017-1375-1","article-title":"Overcoming chemotherapy drug resistance by targeting inhibitors of apoptosis proteins (IAPs)","volume":"22","author":"Rathore","year":"2017","journal-title":"Apoptosis"},{"issue":"5","key":"10.1016\/j.bcp.2025.117619_b0220","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1080\/10409238.2021.1934811","article-title":"Cancer cells dysregulate PI3K\/AKT\/mTOR pathway activation to ensure their survival and proliferation: mimicking them is a smart strategy of gammaherpesviruses","volume":"56","author":"Cirone","year":"2021","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"issue":"13","key":"10.1016\/j.bcp.2025.117619_b0225","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15133458","article-title":"Emerging role of glioma stem cells in mechanisms of therapy resistance","volume":"15","author":"Eckerdt","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.bcp.2025.117619_b0230","doi-asserted-by":"crossref","first-page":"853","DOI":"10.2174\/1389203724666230822100131","article-title":"BH3 mimetic peptides: an effective strategy to complement anticancer therapy","volume":"24","author":"Saraswathy","year":"2023","journal-title":"Curr. Protein Pept. Sci."},{"issue":"11","key":"10.1016\/j.bcp.2025.117619_b0235","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16112089","article-title":"Understanding the significance of hypoxia-inducible factors (HIFs) in glioblastoma: a systematic review","volume":"16","author":"Begagi\u0107","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.bcp.2025.117619_b0240","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14051176","article-title":"Current understanding of hypoxia in glioblastoma multiforme and its response to immunotherapy","volume":"14","author":"Park","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.bcp.2025.117619_b0245","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41580-020-0227-y","article-title":"Cellular adaptation to hypoxia through hypoxia inducible factors and beyond","volume":"21","author":"Lee","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"22","key":"10.1016\/j.bcp.2025.117619_b0250","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222212608","article-title":"Hypoxia: the cornerstone of glioblastoma","volume":"22","author":"Dom\u00e8nech","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2025.117619_b0255","article-title":"Modulation of mitochondrial dysfunction: Mechanisms and strategies for the use of natural products to treat stroke","author":"Qin","year":"2025","journal-title":"Neural Regen. Res."},{"issue":"7","key":"10.1016\/j.bcp.2025.117619_b0260","doi-asserted-by":"crossref","DOI":"10.3390\/ph16071020","article-title":"Recent advances in potential health benefits of quercetin","volume":"16","author":"Aghababaei","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"issue":"3","key":"10.1016\/j.bcp.2025.117619_b0265","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s10522-025-10249-4","article-title":"ATM and p53 in aging and cancer: a double-edged sword in genomic integrity","volume":"26","author":"Pandey","year":"2025","journal-title":"Biogerontology"},{"issue":"7","key":"10.1016\/j.bcp.2025.117619_b0270","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1007\/s12094-024-03841-6","article-title":"TP53 mutations and MDM2 polymorphisms in breast and ovarian cancers: amelioration by drugs and natural compounds","volume":"27","author":"Chakraborty","year":"2025","journal-title":"Clin. Transl. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2025.117619_b0275","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41392-025-02299-4","article-title":"Glioblastoma at the crossroads: current understanding and future therapeutic horizons","volume":"10","author":"Singh","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bcp.2025.117619_b0280","doi-asserted-by":"crossref","unstructured":"S.K. Ray, S. Mukherjee, Hypoxia and Regulation of Cancer Cell Stemness. Hypoxia and Tumor Microenvironment: Implications for Cancer Therapy, 2025, pp. 149\u2013164.","DOI":"10.1007\/978-981-96-1016-7_8"},{"issue":"1","key":"10.1016\/j.bcp.2025.117619_b0285","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s12943-025-02345-3","article-title":"A comprehensive overview of ovarian cancer stem cells: correlation with high recurrence rate, underlying mechanisms, and therapeutic opportunities","volume":"24","author":"Alizadeh","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bcp.2025.117619_b0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104895","article-title":"Role of Bcl-2 family anti-apoptosis inhibition in overcoming therapeutic resistance in prostate cancer: a systematic review","author":"Jaya","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"1","key":"10.1016\/j.bcp.2025.117619_b0295","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12929-020-0627-5","article-title":"Anti-apoptotic proteins in the autophagic world: an update on functions of XIAP, Survivin, and BRUCE","volume":"27","author":"Cheung","year":"2020","journal-title":"J. Biomed. Sci."},{"issue":"6","key":"10.1016\/j.bcp.2025.117619_b0300","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.3390\/ijms25063228","article-title":"Cellular dynamics of Fas-associated death domain in the regulation of cancer and inflammation","volume":"25","author":"Ranjan","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2025.117619_b0305","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1501659","article-title":"Targeting caspase-8: a new strategy for combating hepatocellular carcinoma","volume":"15","author":"Chen","year":"2024","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.bcp.2025.117619_b0310","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.3390\/cancers14102446","article-title":"Role of cytokines and chemokines in angiogenesis in a tumor context","volume":"14","author":"Geindreau","year":"2022","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.bcp.2025.117619_b0315","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s43556-022-00110-2","article-title":"Targeting the PI3K\/AKT\/mTOR and RAF\/MEK\/ERK pathways for cancer therapy","volume":"3","author":"Li","year":"2022","journal-title":"Mol. Biomed."},{"issue":"1","key":"10.1016\/j.bcp.2025.117619_b0320","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41392-022-01080-1","article-title":"Hypoxia signaling in human health and diseases: implications and prospects for therapeutics","volume":"7","author":"Luo","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"8","key":"10.1016\/j.bcp.2025.117619_b0325","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.3390\/biom15081190","article-title":"Contribution and regulation of HIF-1\u03b1 in testicular injury induced by diabetes mellitus","volume":"15","author":"Wang","year":"2025","journal-title":"Biomolecules"},{"key":"10.1016\/j.bcp.2025.117619_b0330","article-title":"Crosstalk between hypoxia-inducible factor (HIF) and lncRNAs in digestive tumors: from molecular mechanisms to clinical translation","volume":"13","author":"Gan","year":"2025","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.bcp.2025.117619_b0335","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1633163","article-title":"miR-210 promotes the anti-inflammatory phenotype and M2 polarization in murine macrophages","volume":"16","author":"Neculachi","year":"2025","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.bcp.2025.117619_b0340","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3892\/ijmm.2025.5556","article-title":"Epigenetic roles of chromatin remodeling complexes in bone biology and the pathogenesis of bone-related disease","volume":"56","author":"Wu","year":"2025","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.bcp.2025.117619_b0345","series-title":"Hypoxia and Tumor Microenvironment: Implications for Cancer Therapy","first-page":"217","article-title":"Hypoxia-inducible factors: regulation and therapeutic potential","author":"Lin","year":"2025"},{"key":"10.1016\/j.bcp.2025.117619_b0350","first-page":"36","article-title":"Decoding breast cancer treatment resistance through genetic, epigenetic, and immune-regulatory mechanisms: from molecular insights to translational perspectives","volume":"8","author":"Saha","year":"2025","journal-title":"Cancer Drug Resistance"},{"key":"10.1016\/j.bcp.2025.117619_b0355","article-title":"Molecular mediators of metabolic reprogramming in cancer: mechanisms, regulatory networks, and therapeutic strategies","author":"Ahuja","year":"2025","journal-title":"Immunology"},{"issue":"7","key":"10.1016\/j.bcp.2025.117619_b0360","doi-asserted-by":"crossref","first-page":"3301","DOI":"10.3390\/ijms22073301","article-title":"The glioblastoma microenvironment: morphology, metabolism, and molecular signature of glial dynamics to discover metabolic rewiring sequence","volume":"22","author":"Virtuoso","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"45","key":"10.1016\/j.bcp.2025.117619_b0365","article-title":"Micro\u2010nanocarriers based drug delivery technology for blood\u2010brain barrier crossing and brain tumor targeting therapy","volume":"18","author":"Wang","year":"2022","journal-title":"Small"},{"issue":"1","key":"10.1016\/j.bcp.2025.117619_b0370","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/s41419-025-07617-w","article-title":"Temozolomide promotes glioblastoma stemness expression through senescence-associated reprogramming via HIF1\u03b1\/HIF2\u03b1 regulation","volume":"16","author":"Wang","year":"2025","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.bcp.2025.117619_b0375","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00018-025-05642-8","article-title":"Targeting HIF-2\u03b1 in glioblastoma reshapes the immune infiltrate and enhances response to immune checkpoint blockade","volume":"82","author":"Espinoza","year":"2025","journal-title":"Cell. Mol. Life Sci."},{"issue":"6","key":"10.1016\/j.bcp.2025.117619_b0380","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3390\/cells14060437","article-title":"The role of hypoxia-inducible factor-1\u03b1 (HIF-1\u03b1) in the progression of ovarian cancer: perspectives on female infertility","volume":"14","author":"Rahman","year":"2025","journal-title":"Cells"},{"issue":"17","key":"10.1016\/j.bcp.2025.117619_b0385","doi-asserted-by":"crossref","first-page":"11415","DOI":"10.1021\/acs.jmedchem.2c00573","article-title":"Acriflavine, an acridine derivative for biomedical application: current state of the art","volume":"65","author":"Piorecka","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117619_b0390","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.phrs.2019.01.040","article-title":"Allosteric modulation of sigma receptors by BH3 mimetics ABT-737, ABT-263 (Navitoclax) and ABT-199 (Venetoclax)","volume":"142","author":"Lever","year":"2019","journal-title":"Pharmacol. Res."},{"issue":"5\u20136","key":"10.1016\/j.bcp.2025.117619_b0395","doi-asserted-by":"crossref","first-page":"155","DOI":"10.18632\/genesandcancer.176","article-title":"Tumor metabolism regulating chemosensitivity in ovarian cancer","volume":"9","author":"Han","year":"2018","journal-title":"Genes Cancer"},{"key":"10.1016\/j.bcp.2025.117619_b0400","doi-asserted-by":"crossref","first-page":"0170","DOI":"10.34133\/bmr.0170","article-title":"Recent tumor necrosis factor-related apoptosis-inducing ligand engineering strategies for precise strike therapy against tumor","volume":"29","author":"Lee","year":"2025","journal-title":"Biomater. Res."},{"issue":"1","key":"10.1016\/j.bcp.2025.117619_b0405","doi-asserted-by":"crossref","DOI":"10.1111\/bcpt.14110","article-title":"Optimizing autophagy modulation for enhanced TRAIL\u2010mediated therapy: Unveiling the superiority of late\u2010stage inhibition over early\u2010stage inhibition to overcome therapy resistance in cancer","volume":"136","author":"Zinnah","year":"2025","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.bcp.2025.117619_b0410","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci15080884","article-title":"Redox-regulated pathways in glioblastoma stem-like cells: mechanistic insights and therapeutic implications","author":"Esteban-Rom\u00e1n","year":"2025","journal-title":"Brain Sci."},{"issue":"5","key":"10.1016\/j.bcp.2025.117619_b0415","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.3390\/ijms25052529","article-title":"Glioblastoma therapy: past, present and future","volume":"25","author":"Obrador","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.bcp.2025.117619_b0420","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1158\/1535-7163.MCT-08-0981","article-title":"The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects","volume":"8","author":"Schwartz","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bcp.2025.117619_b0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.jphotobiol.2022.112537","article-title":"Inhibition of hypoxia-inducible factor 1 by acriflavine renders glioblastoma sensitive for photodynamic therapy","volume":"234","author":"Ma","year":"2022","journal-title":"J. Photochem. Photobiol. B Biol."},{"issue":"1","key":"10.1016\/j.bcp.2025.117619_b0430","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s11060-023-04456-7","article-title":"Activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrence of glioblastoma","volume":"165","author":"Strowd","year":"2023","journal-title":"J. Neurooncol"},{"issue":"5","key":"10.1016\/j.bcp.2025.117619_b0435","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/neuonc\/noac234","article-title":"Neurological applications of belzutifan in von Hippel-Lindau disease","volume":"25","author":"Zhang","year":"2023","journal-title":"Neuro Oncol."},{"issue":"19","key":"10.1016\/j.bcp.2025.117619_b0440","doi-asserted-by":"crossref","first-page":"9047","DOI":"10.1158\/0008-5472.CAN-05-1235","article-title":"Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity","volume":"65","author":"Kong","year":"2005","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.bcp.2025.117619_b0445","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1097\/NEN.0000000000000210","article-title":"Targeting hypoxia-inducible factor 1\u03b1 in a new orthotopic model of glioblastoma recapitulating the hypoxic tumor microenvironment","volume":"74","author":"Nigim","year":"2015","journal-title":"J. Neuropathol. Exp. Neurol."},{"issue":"11","key":"10.1016\/j.bcp.2025.117619_b0450","doi-asserted-by":"crossref","first-page":"e432","DOI":"10.1038\/cddis.2012.163","article-title":"ABT-737 promotes tBid mitochondrial accumulation to enhance TRAIL-induced apoptosis in glioblastoma cells","volume":"3","author":"Cristofanon","year":"2012","journal-title":"Cell Death Dis."},{"issue":"7","key":"10.1016\/j.bcp.2025.117619_b0455","doi-asserted-by":"crossref","first-page":"632","DOI":"10.3390\/cells13070632","article-title":"A novel approach for glioblastoma treatment by combining apoptosis inducers (TMZ, MTX, and Cytarabine) with EVA (Eltanexor, Venetoclax, and A1210477) inhibiting XPO1, Bcl-2, and Mcl-1","volume":"13","author":"Zhao","year":"2024","journal-title":"Cells"},{"issue":"7","key":"10.1016\/j.bcp.2025.117619_b0460","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1158\/1541-7786.MCR-13-0650","article-title":"PI3K and Bcl-2 inhibition primes glioblastoma cells to apoptosis through downregulation of Mcl-1 and Phospho-BAD","volume":"12","author":"Pareja","year":"2014","journal-title":"Mol. Cancer Res."},{"issue":"2","key":"10.1016\/j.bcp.2025.117619_b0465","first-page":"158","article-title":"Dulanermin in cancer therapy: still much to do","volume":"1","author":"Quintavalle","year":"2012","journal-title":"Translat. Lung Cancer Res."},{"key":"10.1016\/j.bcp.2025.117619_b0470","doi-asserted-by":"crossref","unstructured":"C. Mom, et al. Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase 1 study in patients with advanced solid malignancies, in: EJC Supplements, Pergamon-Elsevier Science Ltd the Boulevard, Langford Lane, Kidlington, 2006.","DOI":"10.1016\/S1359-6349(06)70207-5"},{"issue":"Supplement_2","key":"10.1016\/j.bcp.2025.117619_b0475","doi-asserted-by":"crossref","first-page":"S173","DOI":"10.1093\/neuonc\/noae031","article-title":"ACTION: a randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma","volume":"26","author":"Arrillaga-Romany","year":"2024","journal-title":"Neuro Oncol."},{"issue":"34","key":"10.1016\/j.bcp.2025.117619_b0480","doi-asserted-by":"crossref","first-page":"56110","DOI":"10.18632\/oncotarget.18125","article-title":"Vorinostat suppresses hypoxia signaling by modulating nuclear translocation of hypoxia inducible factor 1 alpha","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.bcp.2025.117619_b0485","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3390\/epigenomes2010005","article-title":"Panobinostat potentiates temozolomide effects and reverses epithelial\u2013mesenchymal transition in glioblastoma cells","volume":"2","author":"Urdiciain","year":"2018","journal-title":"Epigenomes"},{"issue":"1","key":"10.1016\/j.bcp.2025.117619_b0490","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1038\/s41598-021-81841-0","article-title":"Phase 2 trial of hypoxia activated evofosfamide (TH302) for treatment of recurrent bevacizumab-refractory glioblastoma","volume":"11","author":"Brenner","year":"2021","journal-title":"Sci. Rep."},{"issue":"12","key":"10.1016\/j.bcp.2025.117619_b0495","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1080\/17425247.2024.2429702","article-title":"Innovative drug delivery strategies for targeting glioblastoma: overcoming the challenges of the tumor microenvironment","volume":"21","author":"Khot","year":"2024","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.bcp.2025.117619_b0500","doi-asserted-by":"crossref","first-page":"6757","DOI":"10.2147\/IJN.S470478","article-title":"Liposomal nanomaterials: a rising star in glioma treatment","author":"Gan","year":"2024","journal-title":"Int. J. Nanomed."},{"issue":"5","key":"10.1016\/j.bcp.2025.117619_b0505","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.3390\/biomedicines13051188","article-title":"Epigenetic therapies in melanoma\u2014targeting DNA methylation and histone modification","volume":"13","author":"Tigu","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.bcp.2025.117619_b0510","unstructured":"M. Prelli, Standard therapy boosts glioblastoma stem-like cell resistance to apoptosis and confers sensitivity to BH3 mimetics, 2025."},{"key":"10.1016\/j.bcp.2025.117619_b0515","series-title":"Flexible Electronics Integrated into Increasingly Complex Glioblastoma Models for the Study of Pulsed Electric Fields Effects","author":"Lefevre","year":"2022"},{"issue":"13","key":"10.1016\/j.bcp.2025.117619_b0520","doi-asserted-by":"crossref","first-page":"6531","DOI":"10.3390\/ijms26136531","article-title":"Epigenetic dysregulation in cancer: implications for gene expression and DNA repair-associated pathways","volume":"26","author":"Rembia\u0142kowska","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2025.117619_b0525","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s40478-025-02046-4","article-title":"Overcoming temozolomide resistance in glioma: recent advances and mechanistic insights","volume":"13","author":"Li","year":"2025","journal-title":"Acta Neuropathol. Commun."},{"issue":"5","key":"10.1016\/j.bcp.2025.117619_b0530","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.3390\/cancers14051176","article-title":"Current understanding of hypoxia in glioblastoma multiforme and its response to immunotherapy","volume":"14","author":"Park","year":"2022","journal-title":"Cancers"},{"issue":"35","key":"10.1016\/j.bcp.2025.117619_b0535","article-title":"Pharmacologic HIF stabilization activates costimulatory receptor expression to increase antitumor efficacy of adoptive T cell therapy","volume":"10","author":"Jackson","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bcp.2025.117619_b0540","unstructured":"J. Wanigasekara, Novel Therapeutic Approaches to Treat Brain Cancer Combining 3D Cell Culture Models, Cold Atmospheric Plasma and Airborne Acoustic, 2023."},{"issue":"16","key":"10.1016\/j.bcp.2025.117619_b0545","doi-asserted-by":"crossref","first-page":"5192","DOI":"10.3390\/molecules27165192","article-title":"Targeting HIF-1\u03b1 by natural and synthetic compounds: a promising approach for anti-cancer therapeutics development","volume":"27","author":"Ghosh","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.bcp.2025.117619_b0550","article-title":"Adaptive mechanisms of tumor therapy resistance driven by tumor microenvironment","volume":"9","author":"Wu","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"issue":"7","key":"10.1016\/j.bcp.2025.117619_b0555","first-page":"266","article-title":"MAPK, PI3K\/Akt pathways, and GSK-3\u03b2 activity in severe acute heart failure in intensive care patients: an updated review","volume":"12","author":"Meco","year":"2025","journal-title":"J. Cardiovasc. Develop. Dis."},{"key":"10.1016\/j.bcp.2025.117619_b0560","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.639628","article-title":"Phytochemicals as a complement to cancer chemotherapy: Pharmacological modulation of the autophagy-apoptosis pathway","volume":"12","author":"Rahman","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"6","key":"10.1016\/j.bcp.2025.117619_b0565","first-page":"1616","article-title":"The effect of curcumin on hypoxia in the tumour microenvironment as a regulatory factor in cancer","volume":"19","author":"Zahedi","year":"2023","journal-title":"Arch. Med. Sci."},{"issue":"7","key":"10.1016\/j.bcp.2025.117619_b0570","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1007\/s12094-021-02770-y","article-title":"Resveratrol as a modulatory of apoptosis and autophagy in cancer therapy","volume":"24","author":"Yang","year":"2022","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.bcp.2025.117619_b0575","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jnutbio.2016.12.011","article-title":"Quercetin induces apoptosis and autophagy in primary effusion lymphoma cells by inhibiting PI3K\/AKT\/mTOR and STAT3 signaling pathways","volume":"41","author":"Granato","year":"2017","journal-title":"J. Nutr. Biochem."},{"issue":"15","key":"10.1016\/j.bcp.2025.117619_b0580","doi-asserted-by":"crossref","first-page":"7050","DOI":"10.3390\/ijms26157050","article-title":"Beyond the walls of troy: a scoping review on pharmacological strategies to enhance drug delivery across the blood\u2013brain barrier and blood\u2013Tumor Barrier","volume":"26","author":"Pinkiewicz","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2025.117619_b0585","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12896-025-00969-3","article-title":"Hypoxia and HIF-1 inhibition enhance lentiviral transduction efficiency: a novel strategy for gene delivery optimization","volume":"25","author":"Huo","year":"2025","journal-title":"BMC Biotech."},{"issue":"13","key":"10.1016\/j.bcp.2025.117619_b0590","doi-asserted-by":"crossref","first-page":"6394","DOI":"10.3390\/ijms26136394","article-title":"Transcription factors and methods for the pharmacological correction of their activity","volume":"26","author":"Guryanova","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.bcp.2025.117619_b0595","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.3390\/biomedicines13051234","article-title":"Dual Inhibition of HIF-1\u03b1 and HIF-2\u03b1 as a promising treatment for VHL-associated hemangioblastomas: a pilot study using patient-derived primary cell cultures","volume":"13","author":"Perona-Moratalla","year":"2025","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.bcp.2025.117619_b0600","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41420-025-02375-2","article-title":"BH3 mimetics augment cytotoxic T cell killing of acute myeloid leukemia via mitochondrial apoptotic mechanism","volume":"11","author":"Saxena","year":"2025","journal-title":"Cell Death Discovery"},{"issue":"7","key":"10.1016\/j.bcp.2025.117619_b0605","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1038\/s41418-022-00977-2","article-title":"BH3 mimetic drugs cooperate with Temozolomide, JQ1 and inducers of ferroptosis in killing glioblastoma multiforme cells","volume":"29","author":"Moujalled","year":"2022","journal-title":"Cell Death Different."},{"issue":"3","key":"10.1016\/j.bcp.2025.117619_b0610","doi-asserted-by":"crossref","first-page":"145","DOI":"10.34172\/jsums.2022.24","article-title":"Therapeutic activities and biological effects of curcumin, as a natural multi-target compound, on human health: a minireview","volume":"24","author":"Paknia","year":"2022","journal-title":"J. Shahrekord Univ. Med. Sci."},{"issue":"6","key":"10.1016\/j.bcp.2025.117619_b0615","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1080\/14737140.2025.2501073","article-title":"The interplay between angiogenesis and cervical cancer: a comprehensive review","volume":"25","author":"Nandi","year":"2025","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.bcp.2025.117619_b0620","article-title":"State-of-the-art photodynamic therapy for malignant gliomas: innovations in photosensitizers and combined therapeutic approaches","volume":"6","author":"Cesca","year":"2025","journal-title":"Explorat. Targeted Anti-tumor Therapy"},{"issue":"7","key":"10.1016\/j.bcp.2025.117619_b0625","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.3390\/ph18071057","article-title":"Polymeric nanoparticle-mediated photodynamic therapy: a synergistic approach for glioblastoma treatment","volume":"18","author":"Aldhubiab","year":"2025","journal-title":"Pharmaceuticals"},{"issue":"10","key":"10.1016\/j.bcp.2025.117619_b0630","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1080\/1061186X.2024.2389892","article-title":"Advancements in curcumin-loaded PLGA nanoparticle delivery systems: progressive strategies in cancer therapy","volume":"32","author":"Keshavarz Shahbaz","year":"2024","journal-title":"J. Drug Target."},{"issue":"1","key":"10.1016\/j.bcp.2025.117619_b0635","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1186\/s12951-022-01650-z","article-title":"Recent advances of metal-based nanoparticles in nucleic acid delivery for therapeutic applications","volume":"20","author":"Sharma","year":"2022","journal-title":"J. Nanobiotechnol."},{"issue":"1","key":"10.1016\/j.bcp.2025.117619_b0640","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s13578-021-00650-0","article-title":"Exosomal delivery of therapeutic modulators through the blood\u2013brain barrier; promise and pitfalls","volume":"11","author":"Heidarzadeh","year":"2021","journal-title":"Cell Biosci."},{"issue":"1","key":"10.1016\/j.bcp.2025.117619_b0645","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1186\/s13287-022-03212-4","article-title":"Mesenchymal stem cell-derived exosomes as a new therapeutic strategy in the brain tumors","volume":"13","author":"Ghasempour","year":"2022","journal-title":"Stem. Cell Res. Ther."},{"issue":"6","key":"10.1016\/j.bcp.2025.117619_b0650","doi-asserted-by":"crossref","first-page":"682","DOI":"10.3390\/pharmaceutics17060682","article-title":"Synergistic cancer therapies enhanced by nanoparticles: advancing Nanomedicine through multimodal strategies","volume":"17","author":"Mousavi-Kiasary","year":"2025","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.bcp.2025.117619_b0655","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12943-025-02321-x","article-title":"Emerging artificial intelligence-driven precision therapies in tumor drug resistance: recent advances, opportunities, and challenges","volume":"24","author":"Mao","year":"2025","journal-title":"Mol. Cancer"},{"issue":"14","key":"10.1016\/j.bcp.2025.117619_b0660","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.7150\/ijms.112724","article-title":"Overcoming the delivery challenges in CRISPR\/Cas9 Gene editing for effective cancer treatment: a review of delivery systems","volume":"22","author":"Tang","year":"2025","journal-title":"Int. J. Med. Sci."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225008846?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225008846?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T20:08:49Z","timestamp":1773864529000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295225008846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":132,"alternative-id":["S0006295225008846"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117619","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interplay between hypoxia-inducible factors and apoptosis in glioblastoma","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117619","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"117619"}}